Prevention of glucocorticoid induced bone changes with beta-ecdysone

Weiwei Dai, Li Jiang, Yu An Evan Lay, Haiyan Chen, Guoqin Jin, Hongliang Zhang, Alexander Kot, Robert O. Ritchie, Nancy E Lane, Wei Yao

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Beta-ecdysone (βEcd) is a phytoecdysteroid found in the dry roots and seeds of the asteraceae and achyranthes plants, and is reported to increase osteogenesis in vitro. Since glucocorticoid (GC) excess is associated with a decrease in bone formation, the purpose of this study was to determine if treatment with βEcd could prevent GC-induced osteoporosis. Two-month-old male Swiss-Webster mice (n = 8-10/group) were randomized to either placebo or slow release prednisolone pellets (3.3. mg/kg/day) and treated with vehicle control or βEcd (0.5 mg/kg/day) for 21 days. GC treatment inhibited age-dependent trabecular gain and cortical bone expansion and this was accompanied by a 30-50% lower bone formation rate (BFR) at both the endosteal and periosteal surfaces. Mice treated with only βEcd significantly increased bone formation on the endosteal and periosteal bone surfaces, and increased cortical bone mass were their controls to compare to GC alone. Concurrent treatment of βEcd and GC completely prevented the GC-induced reduction in BFR, trabecular bone volume and partially prevented cortical bone loss. In vitro studies determined that βEcd prevented the GC increase in autophagy of the bone marrow stromal cells as well as in whole bone. In summary, βEcd prevented GC induced changes in bone formation, bone cell viability and bone mass. Additional studies are warranted of βEcd for the treatment of GC induced bone loss.

Original languageEnglish (US)
Pages (from-to)48-57
Number of pages10
JournalBone
Volume74
DOIs
StatePublished - May 1 2015

Fingerprint

Ecdysterone
Ecdysone
Glucocorticoids
Osteogenesis
Bone and Bones
Achyranthes
Asteraceae
Autophagy
Therapeutics
Prednisolone
Mesenchymal Stromal Cells
Osteoporosis
Cell Survival
Seeds
Placebos

Keywords

  • Autophagy
  • Beta-ecdysone (βEcd)
  • Bone formation
  • Glucocorticoid

ASJC Scopus subject areas

  • Physiology
  • Endocrinology, Diabetes and Metabolism
  • Histology

Cite this

Dai, W., Jiang, L., Lay, Y. A. E., Chen, H., Jin, G., Zhang, H., ... Yao, W. (2015). Prevention of glucocorticoid induced bone changes with beta-ecdysone. Bone, 74, 48-57. https://doi.org/10.1016/j.bone.2015.01.001

Prevention of glucocorticoid induced bone changes with beta-ecdysone. / Dai, Weiwei; Jiang, Li; Lay, Yu An Evan; Chen, Haiyan; Jin, Guoqin; Zhang, Hongliang; Kot, Alexander; Ritchie, Robert O.; Lane, Nancy E; Yao, Wei.

In: Bone, Vol. 74, 01.05.2015, p. 48-57.

Research output: Contribution to journalArticle

Dai, W, Jiang, L, Lay, YAE, Chen, H, Jin, G, Zhang, H, Kot, A, Ritchie, RO, Lane, NE & Yao, W 2015, 'Prevention of glucocorticoid induced bone changes with beta-ecdysone', Bone, vol. 74, pp. 48-57. https://doi.org/10.1016/j.bone.2015.01.001
Dai W, Jiang L, Lay YAE, Chen H, Jin G, Zhang H et al. Prevention of glucocorticoid induced bone changes with beta-ecdysone. Bone. 2015 May 1;74:48-57. https://doi.org/10.1016/j.bone.2015.01.001
Dai, Weiwei ; Jiang, Li ; Lay, Yu An Evan ; Chen, Haiyan ; Jin, Guoqin ; Zhang, Hongliang ; Kot, Alexander ; Ritchie, Robert O. ; Lane, Nancy E ; Yao, Wei. / Prevention of glucocorticoid induced bone changes with beta-ecdysone. In: Bone. 2015 ; Vol. 74. pp. 48-57.
@article{97c22cf12e1f4600b9c7449f95e5728c,
title = "Prevention of glucocorticoid induced bone changes with beta-ecdysone",
abstract = "Beta-ecdysone (βEcd) is a phytoecdysteroid found in the dry roots and seeds of the asteraceae and achyranthes plants, and is reported to increase osteogenesis in vitro. Since glucocorticoid (GC) excess is associated with a decrease in bone formation, the purpose of this study was to determine if treatment with βEcd could prevent GC-induced osteoporosis. Two-month-old male Swiss-Webster mice (n = 8-10/group) were randomized to either placebo or slow release prednisolone pellets (3.3. mg/kg/day) and treated with vehicle control or βEcd (0.5 mg/kg/day) for 21 days. GC treatment inhibited age-dependent trabecular gain and cortical bone expansion and this was accompanied by a 30-50{\%} lower bone formation rate (BFR) at both the endosteal and periosteal surfaces. Mice treated with only βEcd significantly increased bone formation on the endosteal and periosteal bone surfaces, and increased cortical bone mass were their controls to compare to GC alone. Concurrent treatment of βEcd and GC completely prevented the GC-induced reduction in BFR, trabecular bone volume and partially prevented cortical bone loss. In vitro studies determined that βEcd prevented the GC increase in autophagy of the bone marrow stromal cells as well as in whole bone. In summary, βEcd prevented GC induced changes in bone formation, bone cell viability and bone mass. Additional studies are warranted of βEcd for the treatment of GC induced bone loss.",
keywords = "Autophagy, Beta-ecdysone (βEcd), Bone formation, Glucocorticoid",
author = "Weiwei Dai and Li Jiang and Lay, {Yu An Evan} and Haiyan Chen and Guoqin Jin and Hongliang Zhang and Alexander Kot and Ritchie, {Robert O.} and Lane, {Nancy E} and Wei Yao",
year = "2015",
month = "5",
day = "1",
doi = "10.1016/j.bone.2015.01.001",
language = "English (US)",
volume = "74",
pages = "48--57",
journal = "Bone",
issn = "8756-3282",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Prevention of glucocorticoid induced bone changes with beta-ecdysone

AU - Dai, Weiwei

AU - Jiang, Li

AU - Lay, Yu An Evan

AU - Chen, Haiyan

AU - Jin, Guoqin

AU - Zhang, Hongliang

AU - Kot, Alexander

AU - Ritchie, Robert O.

AU - Lane, Nancy E

AU - Yao, Wei

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Beta-ecdysone (βEcd) is a phytoecdysteroid found in the dry roots and seeds of the asteraceae and achyranthes plants, and is reported to increase osteogenesis in vitro. Since glucocorticoid (GC) excess is associated with a decrease in bone formation, the purpose of this study was to determine if treatment with βEcd could prevent GC-induced osteoporosis. Two-month-old male Swiss-Webster mice (n = 8-10/group) were randomized to either placebo or slow release prednisolone pellets (3.3. mg/kg/day) and treated with vehicle control or βEcd (0.5 mg/kg/day) for 21 days. GC treatment inhibited age-dependent trabecular gain and cortical bone expansion and this was accompanied by a 30-50% lower bone formation rate (BFR) at both the endosteal and periosteal surfaces. Mice treated with only βEcd significantly increased bone formation on the endosteal and periosteal bone surfaces, and increased cortical bone mass were their controls to compare to GC alone. Concurrent treatment of βEcd and GC completely prevented the GC-induced reduction in BFR, trabecular bone volume and partially prevented cortical bone loss. In vitro studies determined that βEcd prevented the GC increase in autophagy of the bone marrow stromal cells as well as in whole bone. In summary, βEcd prevented GC induced changes in bone formation, bone cell viability and bone mass. Additional studies are warranted of βEcd for the treatment of GC induced bone loss.

AB - Beta-ecdysone (βEcd) is a phytoecdysteroid found in the dry roots and seeds of the asteraceae and achyranthes plants, and is reported to increase osteogenesis in vitro. Since glucocorticoid (GC) excess is associated with a decrease in bone formation, the purpose of this study was to determine if treatment with βEcd could prevent GC-induced osteoporosis. Two-month-old male Swiss-Webster mice (n = 8-10/group) were randomized to either placebo or slow release prednisolone pellets (3.3. mg/kg/day) and treated with vehicle control or βEcd (0.5 mg/kg/day) for 21 days. GC treatment inhibited age-dependent trabecular gain and cortical bone expansion and this was accompanied by a 30-50% lower bone formation rate (BFR) at both the endosteal and periosteal surfaces. Mice treated with only βEcd significantly increased bone formation on the endosteal and periosteal bone surfaces, and increased cortical bone mass were their controls to compare to GC alone. Concurrent treatment of βEcd and GC completely prevented the GC-induced reduction in BFR, trabecular bone volume and partially prevented cortical bone loss. In vitro studies determined that βEcd prevented the GC increase in autophagy of the bone marrow stromal cells as well as in whole bone. In summary, βEcd prevented GC induced changes in bone formation, bone cell viability and bone mass. Additional studies are warranted of βEcd for the treatment of GC induced bone loss.

KW - Autophagy

KW - Beta-ecdysone (βEcd)

KW - Bone formation

KW - Glucocorticoid

UR - http://www.scopus.com/inward/record.url?scp=84921512406&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921512406&partnerID=8YFLogxK

U2 - 10.1016/j.bone.2015.01.001

DO - 10.1016/j.bone.2015.01.001

M3 - Article

VL - 74

SP - 48

EP - 57

JO - Bone

JF - Bone

SN - 8756-3282

ER -